These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 17572895

  • 1. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, Chen Y, Zeng XY, You JH, Qian Y, Shen ZX.
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [Abstract] [Full Text] [Related]

  • 2. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
    Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M.
    Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
    [Abstract] [Full Text] [Related]

  • 3. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [Abstract] [Full Text] [Related]

  • 4. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 5. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM.
    Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec 15; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 7. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec 15; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 8. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec 15; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B.
    J Clin Oncol; 2005 Jun 20; 23(18):4117-26. PubMed ID: 15867204
    [Abstract] [Full Text] [Related]

  • 10. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S, Yu Y, Jun-Min L, Jian-Qing M, Qiu-Sheng C, Yu C, Wei-Li Z, Jian-Hua Y, Hui-Jin Z, Yan W, Li W, Shu C, Zhi-Xiang S.
    Ann Hematol; 2009 Sep 20; 88(9):863-9. PubMed ID: 19205655
    [Abstract] [Full Text] [Related]

  • 11. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
    Rueda A, Sabin P, Rifá J, Llanos M, Gómez-Codina J, Lobo F, García R, Herrero J, Provencio M, Jara C, Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).
    Hematol Oncol; 2008 Mar 20; 26(1):27-32. PubMed ID: 17868190
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups.
    Br J Haematol; 2008 Feb 20; 140(4):411-9. PubMed ID: 18162120
    [Abstract] [Full Text] [Related]

  • 13. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2002 Jun 15; 94(12):3083-8. PubMed ID: 12115338
    [Abstract] [Full Text] [Related]

  • 14. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Aug 01; 23(22):5027-33. PubMed ID: 15955905
    [Abstract] [Full Text] [Related]

  • 15. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 16. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
    Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K.
    Ann Hematol; 2010 Sep 20; 89(9):897-904. PubMed ID: 20414658
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 20; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 18. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.
    J Clin Oncol; 2006 Jul 01; 24(19):3121-7. PubMed ID: 16754935
    [Abstract] [Full Text] [Related]

  • 19. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 20. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC, Best JH.
    Cancer; 2005 Apr 15; 103(8):1644-51. PubMed ID: 15756658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.